KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $370.1 million.

  • Supernus Pharmaceuticals' Total Liabilities rose 1029.23% to $370.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $370.1 million, marking a year-over-year increase of 1029.23%. This contributed to the annual value of $332.3 million for FY2024, which is 668.72% down from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Total Liabilities of $370.1 million as of Q3 2025, which was up 1029.23% from $318.5 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Total Liabilities high stood at $879.7 million for Q1 2023, and its period low was $316.6 million during Q1 2025.
  • Moreover, its 5-year median value for Total Liabilities was $374.9 million (2024), whereas its average is $572.0 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first soared by 3061.95% in 2021, then crashed by 5737.84% in 2024.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Total Liabilities stood at $873.3 million in 2021, then dropped by 6.53% to $816.3 million in 2022, then crashed by 56.37% to $356.2 million in 2023, then decreased by 6.69% to $332.3 million in 2024, then increased by 11.36% to $370.1 million in 2025.
  • Its Total Liabilities was $370.1 million in Q3 2025, compared to $318.5 million in Q2 2025 and $316.6 million in Q1 2025.